1995

AACR Launches First Clinical Journal: *Clinical Cancer Research*



JOHN MENDELSOHN, MD, FOUNDING EDITOR-IN-CHIEF, 1995-2004

Internationally recognized for demonstrating how the binding of growth factors to cell surface receptors regulates cell function, Dr. Mendelsohn, with his collaborators at the University of California, San Diego, produced monoclonal antibody 225, which inhibits cancer cell proliferation by blocking activation of the tyrosine kinase function of the epidermal growth factor receptor. His subsequent research in both the laboratory and the clinic pioneered the universally adopted concept of anti-receptor and anti-tyrosine kinase therapy that targets key cell signaling pathways as a new form of cancer treatment. Dr. Mendelsohn oversaw a period of substantial growth as President of the University of Texas MD Anderson Cancer Center and now serves as Director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy.

Inaugural Editorial

First Table of Contents

1996

First Impact Factor: 3.162

2003

Identifying the Biologically Active Dose of Sunitinib in Clinical Trials

HIGHLY CITED ARTICLE

In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship



FIGURE 3. SU11248 treatment results in inhibition of SF763T tumor MVD. Mice bearing established (500 mm3) SF763T tumors were treated with SU11248 at 80 mg/kg/day or with vehicle. Tumors were harvested 13 days after initiation of treatment (9 days in the case of vehicle because of rapid tumor growth). Tumors were fixed, paraffin-embedded, sectioned, immunostained for CD31, and counterstained with hematoxylin. Representative X400 fields are shown. Arrows indicate CD31-positive cells (vessel elements).

2004

Journal Begins Twice Monthly Publication

CCR's Top-Cited Article

HIGHLY CITED ARTICLE

Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma



FIGURE 1. Gene expression patterns in basal-like tumors and their correlation with immunohistochemistry. A, the 115 patient/tumor sample dendrogram was taken from the hierarchical clustering analysis presented in Sorlie et al. (2); the tumors were grouped using the breast intrinsic gene list based on 45 paired samples. The basal-like breast cancers are identified in red. The gene expression data for ER, HER2, c-KIT, cytokeratin (CK)5, and HER1 are shown with red squares representing the highest average expression, black representing average gene expression, and green representing the lowest below average. B, 21 basal-like breast cancers identified by gene expression profiling were tested and scored by IHC for CK5/6, HER1, c-KIT, ER, and HER2 (0 = negative, 1 = weak and/or focal staining, 2 = strong diffuse staining), except for HER2, which was scored using a standard (0–3+) scale. ND = not determined. C, representative immunostaining results for four basal-like tumors and a normal breast sample for CK5/6 and HER1.

SCIENTIFIC PUBLISHING CENTENNIAL
1916-2016
AACR American Association for Cancer Research

2004

Reliable Tool Found to Investigate Circulating Tumor Cells in Clinical Utility


HIGHLY CITED ARTICLE

Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases



FIGURE 4. Gallery of CTC images from the CellSpotter Analyzer obtained from 7.5 mL of blood from cancer patients. A shows examples of typical intact CTCs, B shows examples of intact CTCs present as clusters or with odd shapes that are present less frequently, and C provides examples of CTC fragments and apoptotic CTCs. Images presented in C were not included in the CTC counts but are frequently observed in CTC analysis of carcinoma patients.

2005

Institute Director Named Editor-in-Chief

WILLIAM N. HAIT, MD, PHD,
EDITOR-IN-CHIEF, 2005-2007

2007

Multiple Myeloma Expert Appointed Editor-in-Chief

KENNETH C. ANDERSON, MD,
EDITOR-IN-CHIEF, 2007-PRESENT

2014

Impact Factor Reaches Record High of 8.722

SCIENTIFIC PUBLISHING CENTENNIAL
1916-2016
AACR American Association for Cancer Research